¿Qué aporta prosigna en el tratamiento adyuvante de pacientes con cáncer de mama? - page 8

CONCORDANCIA EN GEICAM 2012-09
SUBTYPE CONCORDANCE (95%) (Kappa = 0.89)
Martín et al Curr Med Res Opin. 2015
VHIO LAB
CENTRAL LAB
Luminal A
Luminal B HER2-enriched
Basal-like
Total
Luminal A
125
3
0
0
128
Luminal B
6
58
0
0
64
HER2-enriched
0
0
3
0
3
Basal-like
1
0
0
1
2
Total
132
61
3
1
197*
ROR CONCORDANCE (89%) (Kappa = 0.81)
1,2,3,4,5,6,7 9,10,11,12,13,14,15,16,17,18,...24
Powered by FlippingBook